Agios Pharmaceuticals (NASDAQ:AGIO) PT Raised to $33.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lifted by equities research analysts at The Goldman Sachs Group from $29.00 to $33.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price objective points to a potential downside of 4.46% from the company’s previous close.

Several other research firms also recently weighed in on AGIO. JPMorgan Chase & Co. dropped their target price on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating for the company in a report on Friday, February 23rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 9th. Finally, Royal Bank of Canada lowered their target price on Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating for the company in a report on Friday, February 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $34.75.

Agios Pharmaceuticals Stock Down 0.1 %

NASDAQ:AGIO opened at $34.54 on Friday. The company has a market capitalization of $1.96 billion, a P/E ratio of -5.47 and a beta of 0.81. Agios Pharmaceuticals has a 52 week low of $19.80 and a 52 week high of $35.50. The stock’s fifty day moving average is $30.61 and its two-hundred day moving average is $25.65.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.19. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 39.74%. The company had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $8.37 million. During the same quarter in the prior year, the company posted ($1.47) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was up 46.0% compared to the same quarter last year. Sell-side analysts anticipate that Agios Pharmaceuticals will post -5.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider James William Burns sold 2,642 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total value of $86,049.94. Following the completion of the transaction, the insider now owns 34,518 shares in the company, valued at approximately $1,124,251.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,791 shares of the firm’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total value of $214,642.05. Following the sale, the director now directly owns 137,396 shares in the company, valued at $3,785,259.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider James William Burns sold 2,642 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total value of $86,049.94. Following the transaction, the insider now directly owns 34,518 shares of the company’s stock, valued at $1,124,251.26. The disclosure for this sale can be found here. Insiders sold 16,035 shares of company stock valued at $475,277 in the last three months. 4.24% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its position in shares of Agios Pharmaceuticals by 96.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,429 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 700 shares during the last quarter. Quest Partners LLC purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $41,000. Headlands Technologies LLC increased its position in shares of Agios Pharmaceuticals by 31.3% during the third quarter. Headlands Technologies LLC now owns 9,037 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 2,153 shares in the last quarter. NEOS Investment Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $210,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Agios Pharmaceuticals by 25.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,502 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 2,148 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.